Andrew J. Campa is a member of the Fast Break team at the Los Angeles Times, having previously covered the Eastside and San Gabriel Valley. Before, he worked at several medium and small daily ...
In a bid to put litigation over the safety of its talc products into the rearview mirror, Johnson & Johnson has added another $1.1 billion to its settlement offer, according to media reports. Citing ...
Johnson & Johnson's hopes of quickly building its new cancer drug Rybrevant into a $5 billion product have been undermined by an FDA decision. The US regulator has turned down J&J's marketing ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback